Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin

Abstract: Measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITDpos) has been hampered by the broad heterogeneity of ITD mutations. Using our recently developed FLT3-ITD paired-end next-generation sequencing (NGS)–based MRD ass...

Full description

Saved in:
Bibliographic Details
Main Authors: Frank G. Rücker, Lars Bullinger, Sibylle Cocciardi, Sabrina Skambraks, Tamara J. Luck, Daniela Weber, Julia Krzykalla, Ema Pozek, Isabelle Schneider, Andrea Corbacioglu, Verena I. Gaidzik, Annika Meid, Sophia Aicher, Frank Stegelmann, Anika Schrade, Frauke Theis, Walter Fiedler, Helmut R. Salih, Gerald Wulf, Hans Salwender, Thomas Schroeder, Katharina S. Götze, Michael W. M. Kühn, Michael Lübbert, Richard F. Schlenk, Axel Benner, Felicitas Thol, Michael Heuser, Arnold Ganser, Hartmut Döhner, Konstanze Döhner
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924005792
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952924005792

Similar Items